Trial Profile
A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 May 2020
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 04 May 2020 Status changed from recruiting to discontinued.
- 02 Mar 2015 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov
- 18 Feb 2014 New trial record